What is the treatment for macaron-induced dyskinesia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Macaron-Induced Dyskinesia

The primary treatment for macaron-induced dyskinesia is low-dose voltage-gated sodium channel blockers, with carbamazepine or oxcarbazepine being the first-line options due to their high efficacy and safety profile.

Understanding Dyskinesias

Dyskinesias are abnormal involuntary movements characterized by excessive movement, typically choreiform in nature. They can be caused by various conditions including:

  • Systemic, metabolic, or structural conditions
  • Drug-induced causes (most common)
  • Inherited degenerative conditions 1

Treatment Algorithm for Macaron-Induced Dyskinesia

First-Line Treatment

  • Sodium Channel Blockers:
    • Carbamazepine: Initial dose of 50 mg/day (or 1 mg/kg in children), gradually titrated based on response 2
    • Oxcarbazepine: Initial dose of 75 mg/day 2
    • Most patients achieve complete remission with low doses (carbamazepine 50-200 mg/day or oxcarbazepine 75-300 mg/day) 2

Important Considerations for First-Line Treatment

  • Take medication at bedtime to minimize dizziness side effects 2
  • For Han Chinese patients, HLA-B*15:02 screening should be implemented before initiating carbamazepine to reduce risk of cutaneous reactions 2
  • Approximately 97% of patients report complete or partial relief with these medications 2

Second-Line Options

If patients cannot tolerate carbamazepine/oxcarbazepine or carry HLA-B*15:02:

  • Lamotrigine
  • Topiramate
  • Phenytoin sodium 2

Management of Specific Types of Dyskinesias

For Dystonic Components

  • Anticholinergic medications (e.g., trihexyphenidyl)
  • Antihistaminic medications 2

For Parkinsonian Features

  • Anticholinergic agents
  • Mild dopaminergic agents (amantadine) 2

For Akathisia Components

  • Lowering the dose of any contributing medications
  • β-blockers
  • Benzodiazepines 2

Monitoring and Follow-up

  • Regular assessment for abnormal movements every 3-6 months using standardized scales like the Abnormal Involuntary Movement Scale 2
  • Reevaluation of medication needs after the acute phase or if doses are lowered 2

Special Considerations

  • If dyskinesia persists despite first-line treatment, consider switching to an atypical antipsychotic if the underlying condition requires continued antipsychotic treatment 2
  • For severe cases with orofacial involvement affecting nutrition, alternative medication delivery methods may be required 3
  • In cases where medication-induced dyskinesia is suspected, discontinuation of the offending agent should be considered when clinically appropriate 1, 4

Common Pitfalls to Avoid

  • Misdiagnosis: Akathisia is often misinterpreted as psychotic agitation or anxiety 2
  • Inadequate dosing: Starting with too high a dose of carbamazepine/oxcarbazepine can lead to unnecessary side effects; begin with low doses 2
  • Failure to screen: Not checking HLA-B*15:02 status before initiating carbamazepine in at-risk populations 2
  • Inadequate monitoring: Not regularly assessing for movement disorders in patients on medications that can cause dyskinesias 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.